Ibex Investors LLC bought a new position in Teladoc Health Inc (NYSE:TDOC) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,589 shares of the health services provider’s stock, valued at approximately $224,000.

Several other hedge funds and other institutional investors also recently modified their holdings of TDOC. Principal Financial Group Inc. increased its holdings in Teladoc Health by 3.4% during the 1st quarter. Principal Financial Group Inc. now owns 118,266 shares of the health services provider’s stock worth $4,767,000 after acquiring an additional 3,839 shares during the period. Aperio Group LLC bought a new stake in Teladoc Health during the 2nd quarter worth approximately $201,000. Raymond James Financial Services Advisors Inc. increased its holdings in Teladoc Health by 140.9% during the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 23,736 shares of the health services provider’s stock worth $1,378,000 after acquiring an additional 13,883 shares during the period. TD Asset Management Inc. increased its holdings in Teladoc Health by 28.9% during the 2nd quarter. TD Asset Management Inc. now owns 97,800 shares of the health services provider’s stock worth $5,677,000 after acquiring an additional 21,900 shares during the period. Finally, Commonwealth Equity Services LLC increased its holdings in Teladoc Health by 13.0% during the 2nd quarter. Commonwealth Equity Services LLC now owns 24,464 shares of the health services provider’s stock worth $1,420,000 after acquiring an additional 2,809 shares during the period.

In other news, insider Lewis Levy sold 1,284 shares of the company’s stock in a transaction on Monday, September 17th. The shares were sold at an average price of $77.00, for a total value of $98,868.00. Following the completion of the sale, the insider now owns 1,284 shares of the company’s stock, valued at approximately $98,868. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Stephany Verstraete sold 18,000 shares of the company’s stock in a transaction on Thursday, September 20th. The shares were sold at an average price of $74.79, for a total transaction of $1,346,220.00. Following the completion of the sale, the insider now directly owns 13,925 shares of the company’s stock, valued at approximately $1,041,450.75. The disclosure for this sale can be found here. Insiders sold a total of 237,727 shares of company stock valued at $16,507,946 in the last ninety days. 3.95% of the stock is owned by corporate insiders.

TDOC has been the topic of a number of analyst reports. SunTrust Banks upped their target price on shares of Teladoc Health to $77.00 and gave the stock a “buy” rating in a report on Thursday, August 9th. Leerink Swann assumed coverage on shares of Teladoc Health in a research note on Thursday, August 16th. They issued an “outperform” rating and a $90.00 price target for the company. TheStreet raised shares of Teladoc Health from a “d+” rating to a “c” rating in a research note on Wednesday, August 22nd. KeyCorp boosted their price target on shares of Teladoc Health from $74.00 to $90.00 and gave the stock an “overweight” rating in a research note on Monday, August 27th. Finally, Canaccord Genuity boosted their price target on shares of Teladoc Health from $70.00 to $86.00 and gave the stock a “buy” rating in a research note on Thursday, September 20th. Four investment analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has given a strong buy rating to the stock. Teladoc Health has a consensus rating of “Buy” and an average price target of $85.06.

TDOC stock opened at $59.81 on Thursday. The company has a debt-to-equity ratio of 0.40, a current ratio of 8.99 and a quick ratio of 8.99. Teladoc Health Inc has a one year low of $30.85 and a one year high of $89.05. The company has a market capitalization of $4.19 billion, a price-to-earnings ratio of -36.25 and a beta of 0.92.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Thursday, November 1st. The health services provider reported ($0.34) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.36) by $0.02. Teladoc Health had a negative net margin of 31.32% and a negative return on equity of 14.05%. The business had revenue of $111.00 million during the quarter, compared to analysts’ expectations of $109.94 million. During the same quarter in the previous year, the company earned ($0.55) EPS. The business’s quarterly revenue was up 61.6% compared to the same quarter last year. As a group, equities research analysts forecast that Teladoc Health Inc will post -1.47 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Ibex Investors LLC Takes $224,000 Position in Teladoc Health Inc (TDOC)” was originally reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The legal version of this piece can be read at https://www.watchlistnews.com/ibex-investors-llc-takes-224000-position-in-teladoc-health-inc-tdoc/2664957.html.

About Teladoc Health

Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.

Further Reading: Compound Interest and Why It Matters When Investing

Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc Health Inc (NYSE:TDOC).

Institutional Ownership by Quarter for Teladoc Health (NYSE:TDOC)

Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.